Anakinra and its rapidly expanding role in management of nonarthritic systemic disorders.
Kapoor
Shailendra
S
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D003326:Coronary Circulation / Q000187:drug effects / Q000502:physiology; D003920:Diabetes Mellitus / Q000188:drug therapy; D019332:Endothelin-1 / Q000037:antagonists & inhibitors / Q000097:blood; D006801:Humans; D006930:Hyperalgesia / Q000188:drug therapy; D006976:Hypertension, Pulmonary / Q000188:drug therapy; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use*; D007375:Interleukin-1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D009203:Myocardial Infarction / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D011014:Pneumonia / Q000188:drug therapy; D018124:Receptors, Tumor Necrosis Factor / Q000037:antagonists & inhibitors / Q000378:metabolism; D013577:Syndrome
D018501:Antirheumatic Agents; D019332:Endothelin-1; D053590:Interleukin 1 Receptor Antagonist Protein; D007375:Interleukin-1; D018124:Receptors, Tumor Necrosis Factor